Odyssey Therapeutics raises $168M in Series B

Financing and Partnerships

Oct 13

Written By Frances Benson

https://odysseytx.com/news/

2022

Frances Benson

ARS Pharmaceuticals announces FDA acceptance of NDA for neffy® (epinephrine nasal spray) for the treatment of allergic reactions (type I) including anaphylaxis

Nimbus Therapeutics announces research collaboration and license agreement with Lilly